CLAVELA is a randomised controlled phase III study comparing the survival of patients treated with elacytarabine with the survival of patients receiving the treatment(s) chosen by the investigator.
Key Inclusion Criteria
-
≥ 18 years who have failed 2 or 3 prior induction treatments for AML or;
-
≥ 65 years with adverse cytogenetics who have failed one prior induction treatment for AML
The study will recruit 380 patients at 75 hospitals in the USA, Canada, Europe and Australia.
Hospitals participating in the study (click on the map):
| USA and Canada |
Europe |
Australia |
|
|
|
To refer or enroll patients in the CLAVELA study or to learn more about the trial; visit websites clinicaltrials.gov , e-mail: clavela@clavispharma.com or phone +47 24 11 09 50
